Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 1;2(1):23-29.
doi: 10.1016/j.trci.2015.12.001.

A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure

B R Ott  1 , M A Pelosi  1 , G Tremont  2 , P J Snyder  1
Affiliations

A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure

B R Ott et al. Alzheimers Dement (N Y). .

Abstract

Introduction: This survey characterizes viewpoints of cognitively intact at-risk participants in an Alzheimer prevention registry if given the opportunity to learn their genetic and amyloid PET status.

Methods: 207 participants were offered a 25-item survey. They were asked if they wished to know their ApoE and amyloid PET status, and if so, reasons for wanting to know, or not, and the effects of such information on life plans.

Results: 164 (79.2%) of registrants completed the survey. Among those who were unaware of their ApoE or amyloid PET results, 80% desired to know this information. The most common reasons for wanting disclosure were to participate in research, to arrange personal affairs, to prepare family for illness, and to move life plans closer into the future. When asked if disclosure would help with making plans to end one's life when starting to lose their memory, 12.7% vs. 11.5% responded yes for ApoE and amyloid PET disclosures, respectively. Disclosure of these test results, if required for participation in a clinical trial, would make 15% of people less likely to participate. Likelihood of participation in prevention research and the desire to know test results were not related to scores on brief tests of knowledge about the tests.

Discussion: These results suggest that stakeholders in AD prevention research generally wish to know biological test information about their risk for developing AD to assist in making life plans.

Keywords: Alzheimer; PET; amyloid; apolipoprotein E; clinical trials; prevention; survey.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Knowledge test responses. Abbreviations: APOE, apolipoprotein E; PET, positron emission tomography.
See this image and copyright information in PMC

References

    1. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–279. - PMC - PubMed
    1. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280–292. - PMC - PubMed
    1. Reiman E.M., Langbaum J.B., Fleisher A.S., Caselli R.J., Chen K., Ayutyanont N. Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(Suppl 3):321–329. - PMC - PubMed
    1. Reiman E.M., Langbaum J.B., Tariot P.N. Alzheimer's prevention initiative: A proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med. 2010;4:3–14. - PMC - PubMed
    1. Romero H.R., Welsh-Bohmer K.A., Gwyther L.P., Edmonds H.L., Plassman B.L., Germain C.M. Community engagement in diverse populations for Alzheimer disease prevention trials. Alzheimer Dis Assoc Disord. 2014;28:269–274. - PMC - PubMed

LinkOut - more resources